rsv arexvy - Search News

News

GSK, RSV and EMA

EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,

Medical Dialogues · 1d

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial

Reuters on MSN · 3d

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

STAT4d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

pharmaphorum4d

GSK on top in RSV jab rollout, but is Pfizer closing the gap?

Abrysvo has also been approved as a maternal vaccine to prevent RSV in newborns, an indication that GSK abandoned for Arexvy, but in that category it has to compete with Sanofi and AstraZeneca’s ...

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results